» Articles » PMID: 24373791

Soy Isoflavones and Prostate Cancer: a Review of Molecular Mechanisms

Overview
Date 2013 Dec 31
PMID 24373791
Citations 106
Authors
Affiliations
Soon will be listed here.
Abstract

Soy isoflavones are dietary components for which an association has been demonstrated with reduced risk of prostate cancer (PCa) in Asian populations. However, the exact mechanism by which these isoflavones may prevent the development or progression of PCa is not completely understood. There are a growing number of animal and in vitro studies that have attempted to elucidate these mechanisms. The predominant and most biologically active isoflavones in soy products, genistein, daidzein, equol, and glycetin, inhibit prostate carcinogenesis in some animal models. Cell-based studies show that soy isoflavones regulate genes that control cell cycle and apoptosis. In this review, we discuss the literature relevant to the molecular events that may account for the benefit of soy isoflavones in PCa prevention or treatment. These reports show that although soy isoflavone-induced growth arrest and apoptosis of PCa cells are plausible mechanisms, other chemo protective mechanisms are also worthy of consideration. These possible mechanisms include antioxidant defense, DNA repair, inhibition of angiogenesis and metastasis, potentiation of radio- and chemotherapeutic agents, and antagonism of estrogen- and androgen-mediated signaling pathways. Moreover, other cells in the cancer milieu, such as the fibroblastic stromal cells, endothelial cells, and immune cells, may be targeted by soy isoflavones, which may contribute to soy-mediated prostate cancer prevention. In this review, these mechanisms are discussed along with considerations about the doses and the preclinical models that have been used.

Citing Articles

Reduction of Prostate Cancer Risk: Role of Frequent Ejaculation-Associated Mechanisms.

Hassan M, Flanagan T, Eshaq A, Altamimi O, Altalag H, Alsharif M Cancers (Basel). 2025; 17(5).

PMID: 40075690 PMC: 11898507. DOI: 10.3390/cancers17050843.


Exploring the potential anti-senescence effects of soybean-derived peptide Soymetide in mice hippocampal neurons via the Wnt/β-catenin pathway.

Garg A, Saroj J, Tiwari S, Das U, Shukla N, Ghosh J Front Pharmacol. 2025; 16:1510337.

PMID: 40070562 PMC: 11893861. DOI: 10.3389/fphar.2025.1510337.


Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.

Naponelli V, Piscazzi A, Mangieri D Int J Mol Sci. 2025; 26(3).

PMID: 39940882 PMC: 11818640. DOI: 10.3390/ijms26031114.


Effect of Soy Isoflavone on Prostate Cancer Cell Apoptosis Through Inhibition of STAT3, ERK, and AKT.

Lee Y, Lee C, Choi D, Lee Y, Lee S Curr Issues Mol Biol. 2024; 46(11):12512-12526.

PMID: 39590337 PMC: 11592447. DOI: 10.3390/cimb46110743.


Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer.

Kumar N Cancer Control. 2024; 31:10732748241302863.

PMID: 39573923 PMC: 11583501. DOI: 10.1177/10732748241302863.


References
1.
Swami S, Krishnan A, Moreno J, Bhattacharyya R, Peehl D, Feldman D . Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr. 2006; 137(1 Suppl):205S-210S. DOI: 10.1093/jn/137.1.205S. View

2.
Afaq F, Katiyar S . Polyphenols: skin photoprotection and inhibition of photocarcinogenesis. Mini Rev Med Chem. 2011; 11(14):1200-15. PMC: 3288507. DOI: 10.2174/13895575111091200. View

3.
Tepper C, Vinall R, Wee C, Xue L, Shi X, Burich R . GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007; 67(5):521-35. DOI: 10.1002/pros.20548. View

4.
Cao F, Jin T, Zhou Y . Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene. Biomed Environ Sci. 2006; 19(1):35-41. View

5.
Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View